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A B S T R A C T
Background
Prior guidelines stated that trypanocidal therapy should not be used for treating chronic asymptomatic Trypanosoma cruzi infections.
However, the recent availability of clinical trials reporting high rates of parasitologic cure in children with early chronic T. cruzi infection
have produced changes of these recommendations in some countries. Because of the uncertainty regarding best treatment for this stage
of T. cruzi infections, the literature was reviewed systematically for a synthesis of the available evidence.
Objectives
To assess the effects of trypanocidal therapy for chronic asymptomatic T. cruzi infection
Search methods
We searched The Cochrane Controlled Trials Register (Issue 1, 2000), MEDLINE (start-Nov 1999), EMBASE (start - Feb 2000),
LILACS (start - Feb 2000) and the Tropical Diseases Research Division of WHO database (Start - Feb 2000) . Reference lists of articles
were searched for relevant material.
Selection criteria
Published RCTs of trypanocidal therapy for people with chronic, asymptomatic T. cruzi infections
Data collection and analysis
Two reviewers independently screened papers for inclusion criteria, quality assessment and data extraction. Forms were used to collect
data. Reviewers resolved differences by discussion then a third reviewer if necessary.
Main results
Of 43 papers assessed for inclusion, five RCTs (total population=756) met the inclusion criteria. The quality of the trials was rated
as low (n=3) or intermediate (n=2). Two RCTs tested benznidazole in school children and three tested different agents in adults. The
Odds Ratios and their 95%CI (Fixed models) were: Incidence of ECG abnormalities: 0.41 (0.09, 1.85); Negative seroconversion (AT
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ELISA): 10.91 (6.07, 19.58); Negative xenodiagnosis during the follow up: 5.37 (3.34, 8.64); Standardised mean reduction of antibody
titres: 0.54 (0.31, 0.84). Nitroimidazolic derivatives substantially and significantly modified parasite-related outcomes compared to
placebo. Other agents showed borderline or not significant effect.
Authors’ conclusions
Despite major public health importance, trypanocidal·therapy for chronic asymptomatic T. cruzi infection has been tested in few,
small size RCTs which were designed to assess parasitic-related, but not clinical outcomes. Therefore, the potential of trypanocidal
therapy to prevent Chagas’ disease among asymptomatic, chronically infected subjects is promising, but remains to be evaluated.
Trypanocidal therapy, particularly nitroimidazolic derivatives given to children or adults with positive xenodiagnosis improve parasite-
related outcomes. The large contrast between the burden of Chagas disease and the existing evidence on its prevention points the need
to test these or newer agents in more and larger RCTs that include clinical endpoints.
P L A I N L A N G U A G E S U M M A R Y
Studies testing anti-parasitic drugs for people infected, but still free of Chagas’ disease, are scarce and fail to provide evidence
about them as preventive medications.
Trypanosoma cruzi, a parasite causing Chagas’ disease, infects about 18 million people living across Latin America. About 30% of them
develop a major heart disease in their 30s or 40s, after decades of silent infection. No treatment is considered useful for preventing the
disease among those infected, but still healthy. Drugs aimed to destroy the parasites may have this potential. Reviewers found only five
published trials including 756 participants testing such agents. Although the anti-parasitic activity of most of these compounds was
documented, no study addressed the efficacy of the drugs in terms of signs or symptoms of the disease.
B A C K G R O U N D
Chagas’ heart disease (CHAD) is the result of human infection by
Trypanosoma cruzi. Ninety years after its first description (Chagas
1909) Chagas heart disease is endemic in 21 Latin American coun-
tries, where the WHO estimates that 16-18 million people are
infected and 100 million are at risk (WHO 2000). It accounts for
the loss of 2,740,000 disability adjusted life years (Murray 2000),
four times the burden caused by malaria, schistosomiasis, leprosy
and leishmaniasis altogether in the Americas (Schmunis 1994).
Once primary infection is acquired, spontaneous clinical resolu-
tion occurs in 95%-99% of cases (WHO 1991, Laranja 1956).
Then, chronically infected individuals become seropositive and
remain asymptomatic for the next 10-30 years, when, if the elec-
trocardiogram is normal and no evidence of cardiomegaly or di-
gestive megaviscera is observed at X rays, they are known to be
in the indeterminate phase (IP) (WHO 1991). Of these individ-
uals, about 30% will progress to the chronic phase (CP), which
is characterised by an irreversible dilated cardiomyopathy (Prata;
WHO 1991; Laranja 1956). Until now, the only measure useful
to reduce the burden of Chagas heart disease has been the vector
control, a policy responsible for the interruption of the transmis-
sion of Chagas heart disease in southern South America (PAHO
1998, Schmunis 1996). Despite these advances in reducing the
incidence of T. cruzi infection, the burden of Chagas heart disease
is expected to continue in the future since virtually all the burden
of Chagas heart disease comes from individuals already infected
who progress from the indeterminate phase to the chronic phase.
Unfortunately, the trypanocidal treatment currently available con-
sidered useful only for treating either the acute phase or the reac-
tivation of Chagas heart disease (WHO 1991, Sosa 1999, Fragata
1995). Thus, an effective treatment for chronic T. cruzi infection,
particularly for those individuals still in the indeterminate phase
of Chagas heart disease is a high priority and will be a necessary
complement to the vector control policy to achieve a sustained
reduction of the burden of Chagas heart disease in the mid and
long term.
Nitrofurans, the first trypanocide agents developed, were intro-
duced to treat T. cruzi infections in 1962. Since then, two new
trypanocidal treatments have become available for use in humans.
These are the nitroimidazolic derivatives, nifurtimox (NFTMX)
and benznidazole (BZD) (Cançado 1976, Brener 1975; Apt
1985). However, severe side effects mean that in most endemic
countries BZD alone is used to treat T.cruzi infections (Fragata
1995, Sosa 1999).
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Unfortunately, only a small number of additional agents (other
imidazolic derivatives, purine-analogue agents or ergosterol-syn-
thesis blockers) have been tested in animal or phase I/ phase II
clinical trials (Marr 1986, Urbina 1999, De Castro 1993). In addi-
tion, logistic constraints, limited knowledge of the natural history
of Chagas heart disease as well as the lack of diagnostic tools to
evaluate the success of treatment have made it difficult to define
appropriate follow-up periods and clinical endpoints in clinical
trials (Moncayo 1994).
Other factors have also discouraged the enthusiasm for trypanoci-
dal treatments for Chagas heart disease. The observation of scarce
number of parasites in blood or tissues in hearts of people with
Chagas disease caused doubt about the aetiology of Chagas heart
disease. Moreover, it has been thought that demonstration of T.
cruzi in the blood and tissues is not sufficient cause to develop
Chagas disease. As a result, mechanisms of disease independent of
the effect of parasitic load were proposed (Rossi 1995). More re-
cently however, observations have challenged this concept, giving
to the parasites a critical importance for causation of Chagas heart
disease.
·DNA hybridisation techniques have shown that circulating par-
asitic load and parasitic DNA/antigens in tissues correlate with
the degree of inflammation, which targets only affected organs
(Marinho 1999, Jones 1993, Higuchi 1997).
·Clinical trials using better diagnostic tests and research designs
have reported high rates of cure in children with early chronic
T. cruzi infection and recommend trypanocidal therapy for the
indeterminate phase of Chagas disease. (Sosa 1998, de Andrad
1996).
In addition lack of data on the long term efficacy of trypanocidal
treatments contributed to lack of enthusiasm for their use.
Thus, the debate on the role of parasites in the disease and the
recommendation of trypanocidal therapy for the indeterminate
phase of Chagas heart disease has been re-opened (Bestetti 1996,
Bestetti 1997, Andrade 1997, Ianni 1998). Because of the uncer-
tainty regarding best treatment for this stage of T. cruzi infections
a systematic review of the trial data is appropriate.
O B J E C T I V E S
To provide a synthesis of the best evidence available on the effects
of trypanocidal treatment of asymptomatic T.cruzi infection.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included published trials that randomly allocated participants
with chronic T. cruzi infection, without symptomatic Chagas’
heart disease, to one or more of the trypanocidal drugs (as listed
in De Castro 1993) or to a control treatment or placebo
Types of participants
Participants must not have symptomatic Chagas’ heart disease. No
restrictions on age, gender, country or language were set.
Types of interventions
Oral trypanocidal therapies
e.g. Nitroimidazolic derivatives such as nifurtimox (NFTMX) and
benznidazole (BZD). Other oral trypanocidal therapies allopuri-
nol (ALLOP) and itraconazole (ITRA). In any dose given for at
least 30 days and compared against a control or placebo.
Types of outcome measures
Studies had to include at least one of the following outcomes
CLINICAL OUTCOMES:
All-cause mortality
Sudden death
Incidence of heart failure
Side effects of treatment.
PARASITE-RELATED OUTCOMES
At present there are no direct methods to measure T.cruzi parasite
load. Therefore, some surrogate measures are used to assess this
indirectly. The most common are the serology, where the presence
or absence of “anti-T.cruzi” antibodies found in the blood stream
is measured and a technique of parasitologic diagnosis called “xen-
odiagnosis”.
Serology is carried out in clinical laboratories and has two ele-
ments, quantitative, “what is the concentration of antibodies (pro-
teins called immunoglobulins) in the blood? ” , and qualitative
“is the quantity sufficient for this laboratory to state the patient is
positive for this disease?”. There are several methods for measur-
ing the presence of antibody in the blood. The most commonly
used methods to diagnose Chagas’ disease are ELISA (Enzyme
linked immunosorbent assay), indirect haemaglutination and in-
direct immunofluorescence (IIF). Each has different units of mea-
surement that can be approximated to the quantity of antibody.
Laboratories express the amount of antibodies found in a test de-
pending on the technique used. For example “titres”, when the
technique requires to dilute (with water) the serumbeing tested for
antibodies 2,4,8,16 times etc. Other techniques measure changes
in light absorbance in a colour-producing reaction linked to en-
zymes (ELISA) or the amount of (antibodies in the) serum needed
for producing certain amount of fluorescent light (immunofluo-
rescence). Typically, after any assessment of antibodies for a given
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infectious disease the laboratory will assign a “status” to the reac-
tion as positive or negative i.e. the patient is defined as seroposi-
tive - has the disease, or seronegative, does not have the disease.
Each laboratory has its own “boundaries” for assigning this status
depending on the serological technique used. Thus, the serologi-
cal status is, in the end, a qualitative assumption resulting from a
quantitative assessment.
Xenodiagnosis is a test for parasite infection, in which another
species is used as growth medium for the parasite sought. The
natural vector of T.cruzi (reduviduae) are laboratory bred to ensure
they do not carry any parasites. Reduviduae nymphs are allowed
to feed on the blood of the individual being tested. After their
blood meal the nymphs are reared for some days. The gut contents
of nymphs are then searched for T.cruzi parasites. If parasites are
found in the reduviduae insects, the patient has T.cruzi infection
or “positive xenodiagnosis”.
OUTCOME 1 NEGATIVE SEROCONVERSION
Seroconversion for this review was defined as a qualitative change
in the serological status against T.cruzi after treatment.
“Negative seroconversion” is defined as a change to the serological
reaction against T. cruzi frombeing “seropositive” before randomi-
sation, to become “seronegative” after the treatment. Seropositive
and Seronegative are defined by the laboratories inwhich the blood
was analysed.
OUTCOME 2. ANTIBODY TITRES MEAN REDUCTION
We also looked at the mean reduction of antibody titres after
treatment as an outcome.
OUTCOME 3. NEGATIVE XENODIAGNOSIS AFTER
TREATMENT
The proportion of patients with negative xenodiagnosis after treat-
ment was also considered as outcome of this review.
Search methods for identification of studies
The following electronic sources of biomedical information were
consulted: MEDLINE (start - Nov 1999), EMBASE (start - Feb
2000), LILACS (Start - Feb 2000), The Cochrane Controlled Tri-
als Register (CCTR, Issue 1, 2000) and Tropical Diseases Research
Division at theWHO (start - Feb 2.000). The search was comple-
mented with a hand search of review articles retrieved in previous
systematic appraisal of these studies (Villar 2000).
Except in the case of the CCTR, for consistency, we used the
same search strategy criteria in all databases, with the equivalent
English, Spanish and Portuguese terms for [“Trypanosomiasis” or
“Chagas”] and [“Chemotherapy” or “Treatment”] in the title or
abstract.
Relevant papers were identified in a two step process.
Step 1
Titles and abstracts (or full papers if no abstract available) of all
retrieved citations were screened for pre-selection. References were
pre-selected for further exam when they referred to all the follow-
ing:
a) human participants
b) treatment of Chagas disease
c) trypanocidal agents.
Step 2
Full papers of all pre-selected references were appraised by two re-
viewers independently for inclusion criteria. Differences in opin-
ion were resolved by consensus and a third reviewer opinion if
necessary.
Data collection and analysis
DATA ABSTRACTION AND SYNTHESIS
A “data abstraction” form was designed for collecting informa-
tion from relevant studies. It included general characteristics of the
studies, information on demographics, disease, intervention, fol-
low-up, outcomes and a quality assessment (Jadad 1996). Two in-
dependent reviewers abstracted the information from each study,
and their eventual differences were resolved by discussion and a
third reviewer opinion if necessary. Agreement between reviewers
for quality assessment was calculated. All Kappa coefficients were
calculated by using the PC AGREE program (1994, McMaster
University). A descriptive review of the trials was performed.
DATA ANALYSIS - Clinical endpoints
When appropriate, pooled effect estimates and their 95% confi-
dence intervals of the individual clinical endpoints were obtained
by computing odds ratios (OR) using the method proposed by
Yusuf and Peto (Yusuf 1985) and the random models statistical
approach.
DATA ANALYSIS - Diagnosis of trypanosomiasis and assessment
of parasite load
SEROLOGICAL STATUS, “ANTI-T.cruzi” ANTIBODY
TITRE, XENODIAGNOSIS
Changes in serology were examined quantitatively by pooling the
standardised weighted mean differences after intervention. Indi-
vidual differences were computed by subtracting the mean anti-
body titre after treatment from themean antibody titre at baseline.
For each study the variance of the mean differences was inferred
using the methodology suggested by Follmann (Follmann 1992).
When available, for parasite-related outcomes, both symptomatic
and asymptomatic T. cruzi chronically infected patients were in-
cluded in the analysis.
If appropriate, further stratified analysis by categories (i.e. type of
participants, type of agents) was planned. All computations were
performed using Metaview 4.1 (2000, The Cochrane collabora-
tion software).
R E S U L T S
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Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
All five studies were phase-three RCTs. Four of the five had parallel
design and the other re-allocated patients initially on placebo to
either of two active treatment arms (Apt 1998). In this trial the
comparison All trials were reported as randomised, double blind
and placebo-controlled. General characteristics of the included
studies are described in the Table of Included Studies.
Three of the studies were published originally in English, one in
Portuguese and one in Spanish. Two Studies were conducted in
Brazil (Andrade, Coura 1997), one was conducted in Chile (Apt
1998), one in Argentina (Sosa-Estani) and one in Bolivia (Gianella
1997). Three studies included participants from one location cov-
ering suburban and/or rural populations and twoweremulti centre
studies. The total number of randomised participants in the five
studies was 756. Four papers were published in specialised jour-
nals in parasitology or tropical medicine (Sosa 1998, Apt 1998,
Gianella 1997, Coura 1997) and the other in a general Journal (de
Andrad 1996). No association with pharmaceutical companies or
other potential conflicts of interest were declared in the reports.
In the three studies where the ECG status of participants at base-
line was reported, at least 70% of trial participants were in the
Indeterminate Phase of Chagas disease. Two studies tested BZD
in school children (Andrade, Sosa-Estani) the whereas the other
three (Apt 1998, Coura, Gianella) randomised adults to treatment
with either BZD, NFTMX, allopurinol (ALLOP) or itraconazole
(ITRA). Only one study (Andrade) reported clearly the gender
distribution of participants. In that study 70 of 129 (54.2%) of
participants were male.
Control of re-infection
Three studies (Sosa-Estani, Andrade, Coura) were performed in
endemic areas which were, or had been under epidemiologic vig-
ilance by vector control campaigns. The trialists documented the
probability of re-infection by screening and surveying periodically
the rates of seroconversion. Control of re-infection was not re-
ported in the trials by Apt 1998 and Gianella.
Diagnosis of T. cruzi infection
At least two positive serological tests (ELISA, Indirect haemagluti-
nation and Indirect Immunofluorescence) were required to diag-
nose chronic T. cruzi infection in all studies. Xenodiagnosis was
used as one of the outcomes of the effects of trypanocidal ther-
apy in three of them (Apt 1998, Gianella, Coura) and was em-
ployed as a diagnostic sub study in another (Sosa-Estani). DNA
hybridization methods for parasite counting were not used in any
of the studies. Further biochemical or genetic characterisation of
T. Cruzi were not performed either.
Interventions
Four trypanocidal agents, BZD, ALLOP,NFTMXand ITRAwere
tested in the included studies. Three studies tested the effect of
BZD (BZD) with different regimens: Sosa-Estani tested BZD 5
mg/kg/day for 8 weeks; Andrade tested BZD 7.5 mg/kg/day for
8 weeks and Coura tested BZD 5 mg/kg/day for 30 days. Apt
1998 and Gianella tested ALLOP in similar regimens (8.5 mg/kg/
day or 300 mg T.I.D). The Apt 1998 study tested the effect of
ITRA (6.5 mgs/kg/day for 16 weeks) and Coura tested NFTMX
(5 mg/kg/day for 30 days). All studies were placebo-controlled.
No co-interventions were done in any study. The summary of the
interventions in the included studies is shown in the summary
table of included studies.
Follow-up and drop-outs
Overall follow-up varied from 12 months (Coura, Gianella) to 48
months (Apt 1998, Sosa-Estani). Up to 5-6 time points were used
to perform serological tests and clinical assessments (if needed).
Andrade reported that 86% of participants finished the protocol.
Only one of seventeen dropouts was attributable to side effect of
themedication (BZD). Participants who dropped out of this study
had no clinical or serological differences to the population remain-
ing in the study. Sosa-Estani reported that 6 of 55 (11%) BZD-
treated children dropped out because of side effects (defined in the
study protocol as the need to stop study medication, but no need
for hospitalisation). Apt 1998 reported 62/217 (28.6%) dropouts
in those who received itraconazole compared to 2/187 (1.1%) sub-
jects (symptomatic and asymptomatic) allocated to ALLOP and
attributed that to the length of treatment required with ITRA as
the main cause. Gianella reported 10 dropouts, five for each arm
of treatment.
Risk of bias in included studies
None of the included trials reported methods for randomisation,
methods for concealing the treatment allocation, or methods of
blinding for outcome assessment. None described the characteris-
tics of the placebo either. Two, Andrade and Sosa-Estani, described
the details of the withdrawals during the trial. Andrade performed
an intention-to-treat analysis and reported a sample size calcula-
tion beforehand.
Effects of interventions
Study selection
Five randomised controlled trials were identified as eligible for in-
clusion in this systematic review. Taking all the sources of studies
together, 1306 abstracts were screened for eligibility, from which
87 (6.7%) were considered as potentially relevant. Because of the
overlap among databases, a total of 44 of these studies were pre-
selected for further appraisal. 6 of these studies were located in
LILACS (6) and the Tropical Diseases Research Division database
(1) exclusively, whereas 36 (81.8%) appeared inMEDLINE, over-
lapping with the references placed in EMBASE (17) or the CCTR
(13). Of the 44 papers evaluated in full, 5 (11.4%) met the inclu-
sion criteria. The 39 excluded studies did not contain original data
(n=18), were experimental studies other than RCTs (n=14), did
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not include the target population of this review (n=5), were obser-
vational studies (n=5) or contained duplicated information (n=1).
The Characteristics of excluded studies table summarises the rea-
sons for exclusion of these papers. Putting together all the reasons
for exclusion, agreement for inclusion/exclusion was reached in
42 of the 44 papers (Kappa=0.807, p<0.001) between reviewers.
Of the two studies classified differently in the independent assess-
ment, one was finally considered as an observational study and
the other as a preliminary report of an RCT whose data had been
duplicated by the authors in a further publication. Both studies
were excluded. No third reviewer’s opinion was necessary.
Outcomes and data synthesis
Primary and secondary outcomes were pre-defined in three studies
(Sosa-Estani, Andrade, Gianella). The only clinical outcome eval-
uated was the incidence of ECG changes in those participants in
the indeterminate phase ofChagas disease in two studies (Andrade,
Sosa-Estani, n=198). Another report (Apt 1998) showed data on
electrocardiogram, but not by allocated treatment. Conversely, all
studies reported parasitic-related outcomes before and after the
trypanocidal therapy, using study-specific definitions. Serological
status was reported in three studies (Andrade, Coura, Sosa-Estani,
n=277). Negative seroconversion was assessed as outcome using
different techniques: Coura and Sosa-Estani assessed this outcome
by conventional serology, whereas Andrade used the AT ELISA
technique (Almeida 1995). Sosa-Estani’s RCT AT ELISA results
were reported in a separate publication (Almeida 1999). Xenodi-
agnosis (in terms of rate of randomised participants with negative
tests after treatment) were reported by four studies (Apt 1998,
Coura, Gianella, Sosa-Estani, n=693). Finally, differences in anti-
body titres after receiving trypanocidal therapy were reported in
three studies (Andrade, Sosa-Estani, Gianella, n=230).
The pooled Odds ratios (OR) and their 95% confidence intervals,
as computed by the Yusuf-Peto and the random models methods
were respectively: Incidence of ECG Changes: 0.41 (0.09, 1.85)
and 0.41 (0.07, 2.35); Negative seroconversion, as assessed by AT
ELISA:
10.91 (6.07, 19.58) and 22.33 (8.92, 55.89); Negative xenodiag-
nosis after treatment: 5.37 (3.34, 8.64) and 4.97 (3.08, 8.02); The
pooled antibody titres standardised mean reductions (by subtract-
ing titres before trypanocidal therapy from titres after trypanoci-
dal therapy) using Indirect Immunofluorescence were 0.58 (0.31,
0.84) and 0.54 (0.19, 0.89). Data synthesis results for pooled out-
comes including all information available are shown in the com-
parisons under the tables section.
After pooling the data for these outcomes, heterogeneity among
studies was found for xenodiagnosis (heterogeneity test, p<0.001).
The analysis of this outcome by different categories is shown in the
comparison tables for negative xenodiagnosis across different cate-
gories. Both populations and agents used in the trialswere observed
to account for heterogeneity in the results for this outcome.Among
adults included in the trials heterogeneity was observed (p<0.001).
Adults treated with Nitrosamine derivatives (NFTMX or BZD)
had significantly higher rates of negative xenodiagnosis compared
to adults treatedwith other agentsALLOPor ITRA. Similar results
were observed when the children and adults treated with BZD,
compared to those treated with no nitrosamine derivatives. In-
dividually, BZD and NFTMX treated participants achieved sub-
stantial and significant differences in the rates of negative xenodi-
agnosis after treatment compared to ALLOP and ITRA treated
participants. For adults treated with BZD and NFTMX (Coura)
the OR (95% CI, Yusuf-Peto method) were 31.44 (10.35, 95.47
and 14.82 (4.82, 45.59). It decreased to 2.53 (1.14, 5.64) and
1.54 (0.77, 3.08) in adults treated with ITRA (Apt 1998) and
ALLOP (Apt 1998 and Gianella) respectively. The xenodiagnosis
at baseline was also a source of heterogeneity in the results for this
outcome. The OR (95% CI, using the Yusuf-Peto method) for
negative xenodiagnosis after treatment in participants with posi-
tive xenodiagnosis at the baseline was 16.4 (7.91, 34.03), whereas
for those with negative xenodiagnosis when randomised was 1.30
(0.43, 3.94).
For negative seroconversion, data using conventional serology dif-
fer from the pooled outcome usingATELISA shown above: Coura
reported no changes in the serological status in any of the adults al-
located to either treatment group (Not estimableOR). Sosa-Estani
reported negative seroconversion in 5 of 44 BZD-treated children
and 2 of 44 of placebo-treated children (2P=0.433, Fisher’s exact
test).
Side effects
Of two studies testing BZD in children, 7 of 115 treated dropped
out of the study because of side effects. However, the criteria for
discontinuation were different in both studies. Andrade reported
that less than 5% of participants complained of a variety of minor
symptoms, but rash and pruritus were reported as higher in those
receiving the drug (8/64 with BZD versus 2/65 with Placebo, p=
0.094). Sosa-Estani stated a general good tolerance of children to
BZD and reported no severe side effects, but a 11% incidence of
moderate side effects who dropped out as stated above. Overall,
this study estimated the incidence of side effects as less than 20%.
The only study testing BZD in adults reported a non quantified
variety of mild side effects (skin reactions, peripheral neuropathy,
digestive disturbances), but stated that they were less intense than
those seen with NFTMX.
Side effects were also reported in studies testing ALLOP or ITRA.
Apt 1998 stratified tolerance into satisfactory,moderate and unsat-
isfactory and reported no significant differences between placebo
and active treatment. A proportion of 10.3%, 9.7% and 6.7% of
those receiving ALLOP, ITRA and Placebo respectively reported
moderate side effects (p=0.412). However, one case of Stevens-
Johnson syndrome was observed among 155 patients treated with
ALLOP in this study. Gianella also reported one case of severe skin
reaction requiring hospitalisation and steroid treatment among 13
patients evaluated who were allocated to ALLOP. Three studies
(Apt 1998, Andrade, Sosa-Estani) evaluated blood chemistry (liver
enzymes, blood cell counts) but did not report abnormalities in
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childrenunder trypanocidal therapy. Apt 1998 reported a transient
increase in aspartate aminotransferase and alkaline phosphatase in
three of 185 patients receiving ITRA.
D I S C U S S I O N
Chagas heart disease is one example of the contrast between the
burden of a disease and the intensity with which it is researched.
As observed in this review, despite major public health impor-
tance, until now trypanocidal therapy for chronic asymptomatic
T. cruzi infection has been tested in 756 participants, randomised
in five studies, all of them published after 1995. These trials were
not designed to assess clinical outcomes and failed to report key
methodological issues. In addition, because of the sparsity of data
reported, none of the pooled outcomes included all randomised
participants. Thus, all observations on the effects of these agents
for chronic asymptomatic T. cruzi infection should be interpreted
in the light of the small number of participants in studies not
intended to evaluate clinical outcomes. Hence, at present, no ex-
perimental evidence is available to support any recommendation
on the clinical use of trypanocidal therapy for improving clinical
outcomes in chronic asymptomatic T.cruzi infection.
The most important finding in this review was that trypanocidal
therapy, in particular Nitroimidazolic derivatives, improved para-
site-related outcomes. BZD had the greatest effect, it
significantly reduced the proportion of positive xenodiagnoses in
both children and adults, produced negative seroconversion in
children, when serology was tested (using the AT ELISA tech-
nique) and reduced the antibody titres in children (as assessed by
IIF). Conversely studies testing ALLOP or ITRA demonstrated
a substantially lower, though not significant effect on these out-
comes. In addition to the lower effect on parasite load, all the se-
vere side effects reported in the trials included in this review oc-
curred in participants treated with these agents (1.1%). Although
these results are in favour of the use of BZD in children and either
NFTMX or BZD for adults for reducing antibodies or the parasite
load respectively, whether this effect will result in clinical benefit
remains to be proven. Moreover, although effective for parasite
clearance, a variety of side effects were reported in up to 20% of
participants treated with nitroimidazolic derivatives. While these
promising results with parasite-related outcomes provide a spur
to reduce the uncertainty about the clinical effect of these agents,
they also make a case for the development of more and safer try-
panocidal agents available for clinical practice, as suggested by oth-
ers (Urbina 1999).
Most data presented in this review comprised parasite-related out-
comes, assessed either by xenodiagnosis or serology. Xenodiagnosis
was the most widely used test across the studies included in this
review. Despite its obvious problems for patients’ comfort while
being tested, it has remained the best available tool to recover T.
cruzi. However, it fails to detect circulating parasites in 40-80%
of cases, particularly in the Indeterminate Phase of Chagas disease
when parasitaemia is thought to be low (Castro 1999). Such a
lack of sensitivity is in itself a problem to reliably evaluate parasitic
cure (Britto 1999). Indeed, only 70 of 296 (23.6%) of the xen-
odiagnosis performed were positive during the follow-up among
seropositive participants randomised to placebo. The relevance of
this issue is highlighted by the fact that patients with positive xen-
odiagnosis (and perhaps higher parasite loads) at baseline seem to
benefit more from trypanocidal therapy. “Conventional” serology,
the other diagnostic tool, is used to define an individual as in-
fected, if confirmed by at least two different techniques (i.e. in-
direct haemaglutination and ELISA tests accordingly positive in
a given individual) most commonly using “whole” T. cruzi anti-
gens. Its value as a tool for assessment of parasite clearance is still
to be proven. Indeed, both Coura and Sosa-Estani found a sig-
nificantly lower number of positive xenodiagnosis in participants
treated with nitrosamine derivatives, but all treated adults kept
their serological status (Coura) and children (when tested with
conventional serology) did not have a significantly different rate of
negative seroconversion (Sosa-Estani). Conversely, when partici-
pants’ serological status was diagnosed by a more specific serolog-
ical technique, such as AT ELISA, this outcome turned out to be
highly significant. Thus, the extent to which antibodies (in terms
of either serological status or antibody titres) correlates with para-
sitic load (in terms of xenodiagnosis, haemoculture or polymerase
chain reaction) also remains unclear and adds complexity to the
evaluationof chemotherapy forChagas heart disease. Although the
efficacy of nitroimidazolic derivatives was demonstrated in terms
of parasite-related outcomes as compared to placebo, assessing the
absolute trypanocidal effect is still an unsolved problem. Hence,
beside newer trypanocidal agents to be tested, better diagnostic
techniques are also needed for improved appraisal of their effec-
tiveness.
Clinical outcomes were not considered in the RCTs included in
this review. Only two studies reported the incidence of ECG ab-
normalities in participants with Indeterminate Phase of Chagas
heart disease at baseline. Despite a remarkable completion of a
three or four year follow-up of school children of suburban areas
of Brazil and Argentina, only seven abnormal ECGs out of 198
(3.5%) were found. Although such low number of events does
not allow further speculation, it points to the need to take into
account the low-rate of events in the design of further studies.
Likewise, data provided by this review are not sufficient to address
the relationship between parasitic-related and clinical outcomes.
Thus, a better understanding of both the natural history and the
pathogenic role of parasites in Chagas heart disease is needed for
future trypanocidal therapy trials.
A U T H O R S ’ C O N C L U S I O N S
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Implications for practice
Few clinical events were recorded in the trials included in this re-
view. There remains uncertainty in the belief that reducing par-
asitic load may modify the natural history of T. cruzi infection
and therefore the severity of any subsequent heart disease. An ad-
ditional issue for clinicians is the relatively high rate of side ef-
fects found with the use of anti-trypanocidal drugs. If trypanoci-
dal therapy were indicated on individual basis, our review pro-
vides evidence on the differential effect of nitrosamine derivatives
over other type of drugs. Since trypanocidal therapy seems to be
more effective in people with positive xenodiagnosis, these patients
would have higher possibility of benefit from treatment.
Implications for research
Further clinical research in Chagas heart disease embraces many
challenges: conducting more and larger trials that test newer
agents; using better techniques for parasite identification, and us-
ing risk stratification tools for a better estimation of the number
of events. Recording clinical events in trials involving T. cruzi-
infected populations is likely to be more reliable than parasite-
related outcomes and is necessary to provide more definitive, clin-
ically relevant answers on the efficacy of these agents. Prospective
analysis based on clinical outcomes will also provide a better un-
derstanding of the pathogenesis of the disease. Meanwhile, recom-
mendations about trypanocidal therapy in Indeterminate Phase
of Chagas disease should be considered as valid only for parasite-
related outcomes and based on small pieces of evidence. Research
to provide evidence that is lacking remains a high priority for gov-
ernments of Latin America and a challenge for the regional scien-
tific community.
Conclusion
Trypanocidal therapy for chronic asymptomatic T. cruzi infection
has been tested in five randomised controlled trials including 756
randomised participants that were designed to evaluate parasite-re-
lated, but not clinical outcomes. Nitroimidazolic derivatives, espe-
cially BZD improve parasite-related outcomes in both adults and
children. Other agents, such as itraconazole or allopurinol have
much lower,or neutral effect on these outcomes. These promis-
ing results in parasite load reduction are to be considered together
with the rate of side effects reported in the trials of 10% to 20%.
Given the importance of Chagas heart disease for public health in
Latin America, randomised controlled trials should be done that
can add more information to these results should be done so the
effects and harms can be confirmed for clinical endpoints along
with parasitic endpoints.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Andrade
Methods 4
Participants School children
(90% in IP)
Interventions BZD (n=64)
7.5 mg/k/d (8 wk) Placebo (n=65)
Outcomes Serological status recorded
Antibody titres reported
Incidence of ECG abnormalities
Notes Brazil, 1996
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Apt
Methods 1
Participants Adults
(70% in IP)
Interventions ALLOP (n=187)
8.5 mg/k/d (8 wk)
ITRA (n=217)
6 mg/k/d (16 wk)
Placebo (n=24)
Outcomes Xenodiagnosis recorded
ECG changes reported but not described by treatment allocation
Side effects
Notes Chile, 1998
Risk of bias
Item Authors’ judgement Description
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Apt (Continued)
Allocation concealment? No C - Inadequate
Coura
Methods 2
Participants Adults
(% in IP NA)
Interventions BZD (n=26)
5 mg/k/d (4 wk)
NFTMX (n=27)
5 mg/k/d (4 wk)
Placebo (n=24)
Outcomes Serological status recorded
Xenodiagnosis recorded
Notes Brazil, 1997
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Gianella
Methods 2
Participants Adults
(% in IP NA)
Interventions ALLO (n=20)
300mg TID (8wk)
Placebo
Outcomes Antibody titres recorded
Xenodiagnosis recorded
Notes Bolivia, 1997
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Sosa-Estani
Methods 3
Participants School children
(95% in IP)
Interventions BZD (n=55)
5 mg/k/d (8wk)
Placebo
Outcomes Serological status recorded
Antibody titres recorded
Xenodiagnosis recorded
Incidence of ECG abnormalities
Notes Argentina, 1998
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Methods were assessed by using the scale described by Jadad et al 1996. A point is awarded if
1 the study was described as randomised (additional point given if method to generate sequence
was given and was appropriate a point deducted if described and inappropriate).
2 The study is described as double blind ( additional point given if method of blinding
described and appropriate, a point deducted if described and inappropriate) and
3 the number of withdrawals and drop outs are reported
IP: Indeterminate phase
NA: Not available in the report
BZD: Benznidazole
NFTMX: Nifurtimox
ALLO: Allopurinol
ITRA: Itraconazole
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abitbol Study not reporting original data
Aguilera Original studies, other than RCTs
Amato Study not reporting original data
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(Continued)
Amato (a) Study not reporting original data
Andrade (a) Original studies, other than RCTs
Study population out of the scope
Andrade (b) Original studies, other than RCTs
Study population out of the scope
Apt (a) Study not reporting original data
Apt (b) Duplicated data
Bestetti Study not reporting original data
Bocca Tourres Original studies, other than RCTs
Study population out of the scope
Brener Study not reporting original data
Carpintero Original studies, other than RCTs
Coura (a) Study not reporting original data
De Araujo Malta Study not reporting original data
De Oliveira Original studies, other than RCTs
Study population out of the scope
De Oliveira (a) Original studies, other than RCTs
Fernandez Original studies, other than RCTs
Study population out of the scope
Fragata Study not reporting original data
Gallerano Original studies, other than RCTs
Gallerano (a) Original studies, other than RCTs
Gonnert Original studies, other than RCTs
Gutteridge Study not reporting original data
Ivanovic Study not reporting original data
Levi Original studies, other than RCTs
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(Continued)
Levi (a) Study not reporting original data
López-Antuñaño Study not reporting original data
Maldonado Original studies, other than RCTs
Marr Study not reporting original data
Meirovich Original studies, other than RCTs
Mendoza Study not reporting original data
Study related to drugs other than trypanocidal therapy
Prata Original studies, other than RCTs
Rassi Study not reporting original data
Romeu Cançado Study not reporting original data
Rubio Original studies, other than RCTs
Santana Study not reporting original data
Viotti Original studies, other than RCTs
Wegner Original studies, other than RCTs
Study population out of the scope
Wegner (a) Original studies, other than RCTs
Study population out of the scope
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D A T A A N D A N A L Y S E S
Comparison 1. Incidence of ECG abnormalities
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 BZD Children 2 198 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.41 [0.09, 1.85]
Comparison 2. Negative seroconversion
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 BZD - AT ELISA - CHILDREN 2 200 Peto Odds Ratio (Peto, Fixed, 95% CI) 10.91 [6.07, 19.58]
Comparison 3. Negative xenodiagnosis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All populations- All tested agents 4 693 Peto Odds Ratio (Peto, Fixed, 95% CI) 5.37 [3.34, 8.64]
2 Children - BZD 1 85 Peto Odds Ratio (Peto, Fixed, 95% CI) 9.61 [3.76, 24.58]
3 Adults - All tested agents 3 608 Peto Odds Ratio (Peto, Fixed, 95% CI) 4.40 [2.54, 7.63]
4 Adults - Nitrosamine derivatives 1 77 Peto Odds Ratio (Peto, Fixed, 95% CI) 22.24 [8.45, 58.56]
5 Adults - Drugs other than
nitrosamine derivatives
2 531 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.03 [1.04, 3.96]
6 BZD - Children and adults 2 134 Peto Odds Ratio (Peto, Fixed, 95% CI) 15.75 [7.69, 32.27]
7 NFTMX - Adults 1 50 Peto Odds Ratio (Peto, Fixed, 95% CI) 14.82 [4.82, 45.59]
8 ITRA - Adults 1 319 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.53 [1.14, 5.64]
9 ALLOP - Adults 2 377 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.54 [0.77, 3.08]
10 Positive xenodiagnosis at
baseline (Adults)
3 195 Peto Odds Ratio (Peto, Fixed, 95% CI) 16.40 [7.91, 34.03]
11 Negative xenodiagnosis at
baseline (Adults / Drugs other
than nitrosamine derivatives)
1 313 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.30 [0.43, 3.94]
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Comparison 4. Reduction of antibody titres
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All available studies (Indirect
immunofluorescence)
3 230 Std. Mean Difference (IV, Fixed, 95% CI) 0.58 [0.31, 0.84]
Analysis 1.1. Comparison 1 Incidence of ECG abnormalities, Outcome 1 BZD Children.
Review: Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection
Comparison: 1 Incidence of ECG abnormalities
Outcome: 1 BZD Children
Study or subgroup BZD Placebo
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Andrade 1/59 4/58 71.0 % 0.28 [ 0.05, 1.69 ]
Sosa-Estani 1/40 1/41 29.0 % 1.03 [ 0.06, 16.69 ]
Total (95% CI) 99 99 100.0 % 0.41 [ 0.09, 1.85 ]
Total events: 2 (BZD), 5 (Placebo)
Heterogeneity: Chi2 = 0.58, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 1.16 (P = 0.25)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours BZD Favours placebo
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Analysis 2.1. Comparison 2 Negative seroconversion, Outcome 1 BZD - AT ELISA - CHILDREN.
Review: Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection
Comparison: 2 Negative seroconversion
Outcome: 1 BZD - AT ELISA - CHILDREN
Study or subgroup BZD Placebo
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Andrade 37/58 3/54 57.8 % 12.35 [ 5.72, 26.68 ]
Sosa-Estani 24/44 3/44 42.2 % 9.19 [ 3.73, 22.64 ]
Total (95% CI) 102 98 100.0 % 10.91 [ 6.07, 19.58 ]
Total events: 61 (BZD), 6 (Placebo)
Heterogeneity: Chi2 = 0.24, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 8.00 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Placebo Favours BZD
Analysis 3.1. Comparison 3 Negative xenodiagnosis, Outcome 1 All populations- All tested agents.
Review: Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection
Comparison: 3 Negative xenodiagnosis
Outcome: 1 All populations- All tested agents
Study or subgroup Active treatment Placebo
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Apt 314/336 146/165 48.9 % 1.93 [ 0.98, 3.81 ]
Gianella 1/13 0/17 1.4 % 10.05 [ 0.19, 524.76 ]
Sosa-Estani 40/42 21/43 25.6 % 9.61 [ 3.76, 24.58 ]
Coura 43/53 1/24 24.1 % 22.24 [ 8.45, 58.56 ]
Total (95% CI) 444 249 100.0 % 5.37 [ 3.34, 8.64 ]
Total events: 398 (Active treatment), 168 (Placebo)
Heterogeneity: Chi2 = 18.54, df = 3 (P = 0.00034); I2 =84%
Test for overall effect: Z = 6.94 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Placebo Favours Treatment
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Analysis 3.2. Comparison 3 Negative xenodiagnosis, Outcome 2 Children - BZD.
Review: Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection
Comparison: 3 Negative xenodiagnosis
Outcome: 2 Children - BZD
Study or subgroup BZD Placebo
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Sosa-Estani 40/42 21/43 100.0 % 9.61 [ 3.76, 24.58 ]
Total (95% CI) 42 43 100.0 % 9.61 [ 3.76, 24.58 ]
Total events: 40 (BZD), 21 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 4.72 (P < 0.00001)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours Placebo Favours BZD
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Analysis 3.3. Comparison 3 Negative xenodiagnosis, Outcome 3 Adults - All tested agents.
Review: Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection
Comparison: 3 Negative xenodiagnosis
Outcome: 3 Adults - All tested agents
Study or subgroup Active treatment Placebo
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Apt 314/336 146/165 65.7 % 1.93 [ 0.98, 3.81 ]
Coura 43/53 1/24 32.3 % 22.24 [ 8.45, 58.56 ]
Gianella 1/13 0/17 1.9 % 10.05 [ 0.19, 524.76 ]
Total (95% CI) 402 206 100.0 % 4.40 [ 2.54, 7.63 ]
Total events: 358 (Active treatment), 147 (Placebo)
Heterogeneity: Chi2 = 16.56, df = 2 (P = 0.00025); I2 =88%
Test for overall effect: Z = 5.27 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Placebo Favours Treatment
Analysis 3.4. Comparison 3 Negative xenodiagnosis, Outcome 4 Adults - Nitrosamine derivatives.
Review: Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection
Comparison: 3 Negative xenodiagnosis
Outcome: 4 Adults - Nitrosamine derivatives
Study or subgroup Active treatment Placebo
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Coura 43/53 1/24 100.0 % 22.24 [ 8.45, 58.56 ]
Total (95% CI) 53 24 100.0 % 22.24 [ 8.45, 58.56 ]
Total events: 43 (Active treatment), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 6.28 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Placebo Favours Treatment
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Analysis 3.5. Comparison 3 Negative xenodiagnosis, Outcome 5 Adults - Drugs other than nitrosamine
derivatives.
Review: Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection
Comparison: 3 Negative xenodiagnosis
Outcome: 5 Adults - Drugs other than nitrosamine derivatives
Study or subgroup Active treatment Placebo
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Apt 314/336 146/165 97.1 % 1.93 [ 0.98, 3.81 ]
Gianella 1/13 0/17 2.9 % 10.05 [ 0.19, 524.76 ]
Total (95% CI) 349 182 100.0 % 2.03 [ 1.04, 3.96 ]
Total events: 315 (Active treatment), 146 (Placebo)
Heterogeneity: Chi2 = 0.65, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 2.07 (P = 0.038)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Placebo Favours Treatment
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Analysis 3.6. Comparison 3 Negative xenodiagnosis, Outcome 6 BZD - Children and adults.
Review: Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection
Comparison: 3 Negative xenodiagnosis
Outcome: 6 BZD - Children and adults
Study or subgroup BZD Placebo
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Coura 24/26 1/23 41.7 % 31.44 [ 10.35, 95.47 ]
Sosa-Estani 40/42 21/43 58.3 % 9.61 [ 3.76, 24.58 ]
Total (95% CI) 68 66 100.0 % 15.75 [ 7.69, 32.27 ]
Total events: 64 (BZD), 22 (Placebo)
Heterogeneity: Chi2 = 2.55, df = 1 (P = 0.11); I2 =61%
Test for overall effect: Z = 7.53 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Placebo Favours BZD
Analysis 3.7. Comparison 3 Negative xenodiagnosis, Outcome 7 NFTMX - Adults.
Review: Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection
Comparison: 3 Negative xenodiagnosis
Outcome: 7 NFTMX - Adults
Study or subgroup NFTMX Placebo
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Coura 19/27 1/23 100.0 % 14.82 [ 4.82, 45.59 ]
Total (95% CI) 27 23 100.0 % 14.82 [ 4.82, 45.59 ]
Total events: 19 (NFTMX), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 4.70 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Placebo Favours NFTMX
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Analysis 3.8. Comparison 3 Negative xenodiagnosis, Outcome 8 ITRA - Adults.
Review: Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection
Comparison: 3 Negative xenodiagnosis
Outcome: 8 ITRA - Adults
Study or subgroup ITRA Favours placebo
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Apt 147/154 146/165 100.0 % 2.53 [ 1.14, 5.64 ]
Total (95% CI) 154 165 100.0 % 2.53 [ 1.14, 5.64 ]
Total events: 147 (ITRA), 146 (Favours placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.27 (P = 0.023)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours placebo Favours ITRA
Analysis 3.9. Comparison 3 Negative xenodiagnosis, Outcome 9 ALLOP - Adults.
Review: Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection
Comparison: 3 Negative xenodiagnosis
Outcome: 9 ALLOP - Adults
Study or subgroup ALLOP Placebo
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Apt 167/182 146/165 96.9 % 1.45 [ 0.71, 2.94 ]
Gianella 1/13 0/17 3.1 % 10.05 [ 0.19, 524.76 ]
Total (95% CI) 195 182 100.0 % 1.54 [ 0.77, 3.08 ]
Total events: 168 (ALLOP), 146 (Placebo)
Heterogeneity: Chi2 = 0.89, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 1.21 (P = 0.23)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Placebo Favours ALLOP
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Analysis 3.10. Comparison 3 Negative xenodiagnosis, Outcome 10 Positive xenodiagnosis at baseline
(Adults).
Review: Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection
Comparison: 3 Negative xenodiagnosis
Outcome: 10 Positive xenodiagnosis at baseline (Adults)
Study or subgroup Active treatment Placebo
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Apt 56/72 4/16 39.8 % 11.08 [ 3.49, 35.22 ]
Gianella 1/13 0/17 3.4 % 10.05 [ 0.19, 524.76 ]
Coura 43/53 1/24 56.8 % 22.24 [ 8.45, 58.56 ]
Total (95% CI) 138 57 100.0 % 16.40 [ 7.91, 34.03 ]
Total events: 100 (Active treatment), 5 (Placebo)
Heterogeneity: Chi2 = 0.88, df = 2 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 7.52 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Treatment Favours Placebo
Analysis 3.11. Comparison 3 Negative xenodiagnosis, Outcome 11 Negative xenodiagnosis at baseline
(Adults / Drugs other than nitrosamine derivatives).
Review: Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection
Comparison: 3 Negative xenodiagnosis
Outcome: 11 Negative xenodiagnosis at baseline (Adults / Drugs other than nitrosamine derivatives)
Study or subgroup Active treatment Placebo
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Apt 158/164 142/149 100.0 % 1.30 [ 0.43, 3.94 ]
Total (95% CI) 164 149 100.0 % 1.30 [ 0.43, 3.94 ]
Total events: 158 (Active treatment), 142 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.65)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours placebo Favours treatment
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Analysis 4.1. Comparison 4 Reduction of antibody titres, Outcome 1 All available studies (Indirect
immunofluorescence).
Review: Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection
Comparison: 4 Reduction of antibody titres
Outcome: 1 All available studies (Indirect immunofluorescence)
Study or subgroup Active Treatment Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Andrade 58 1409 (1052.12) 54 566 (1400.49) 48.4 % 0.68 [ 0.30, 1.06 ]
Gianella 13 19.69 (317.52) 17 30.12 (234.67) 13.5 % -0.04 [ -0.76, 0.69 ]
Sosa-Estani 44 1.4 (2.31) 44 -0.17 (2.4) 38.1 % 0.66 [ 0.23, 1.09 ]
Total (95% CI) 115 115 100.0 % 0.58 [ 0.31, 0.84 ]
Heterogeneity: Chi2 = 3.20, df = 2 (P = 0.20); I2 =38%
Test for overall effect: Z = 4.25 (P = 0.000021)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours placebo Favours treatment
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